Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1330403
European Journal of Endocrinology, Vol 133, Issue 4, 403-406
Copyright © 1995 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lazar, L.
Right arrow Articles by Pertzelan, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lazar, L.
Right arrow Articles by Pertzelan, A.

Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response

Liora Lazar, Rivka Kauli, Celia Bruchis, Jardena Nordenberg, Avinoam Galatzer and Athalia Pertzelan

Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 1995;133:403–6. ISSN 0804–4643

Exaggerated adrenal response (ExAR), i.e. hypersecretion of both 17-hydroxypregnenolone (170HPreg) and 17-hydroxyprogesterone(17OHP) in response to adrenocorticotropic hormone (ACTH) stimulation, is frequently found in women with polycystic ovary (PCO) syndrome who had precocious adrenarche. In an earlier study we found an abnormal adrenal response in girls with idiopathic true central precocious puberty (CPP) at early stages of puberty. On follow-up it was noted that a significant number of girls with CPP develop PCO-like syndrome at a relatively young age. The aim of the present study was to determine if there is an association between ExAR and early PCO in girls with a history of CPP. Included were 49 girls with a history of CPP, 34 of whom were treated with gonadotropin-releasing hormone (GnRH) analog. All 49 were evaluated at full maturity, at ages 12.5–14 years, 0.5–4 years after menarche or resumption of menses. Of the 49 girls, 20 had at least 3/4 clinical signs of PCO (irregular menses, hirsutism, acne and obesity) and were defined as PCOlike+, whereas 29 did not fulfil the criteria and were considered PCO-like -. Girls with a definite enzyme deficiency were excluded from the study. All participants underwent a combined iv ACTHGnRH test at early follicular phase. The PCO-like + girls all revealed ExAR, i.e. an elevated stimulated 17OHPreg of 63.4 ± 9.6 nmol/l (normal 28.6 ± 9.2 nmol/l) and a normal stimulated 17OHPreg/ 17OHP ratio of 7.1 ± 1.8 (normal 6.2 ± 2.7), whereas all the PCO-like – had a normal adrenal response (30.0 ±8.7 and 5.3 ± 2.0 nmol/l, respectively). Compared to the PCO-like – girls, those with PCO-like± had significantly higher levels of testosterone (1.8 ± 0.7 vs 1.0 ± 0.5 nmol/l; p < 0.001), androstenedione (6.6 ±3.2 vs 4.7 ± 1.8 nmol/l; p < 0.02) and dehydroepiandrosterone sulfate (7.8 ± 4.7 vs 4.2 ± 2.5 µmol/l; p < 0.004), and a trend toward inappropriate luteinizing hormone secretion. The prevalence of ExAR (40.8%) in the mature CPP girls (confined to only PCO-like ±) was similar to that previously found by us in another group of girls with CPP at early puberty (44.6%). In conclusion, our findings indicate that the pattern of adrenal response remains unchanged from early puberty to adulthood and is probably inherent. As only the girls with CPP who developed early PCO syndrome showed ExAR, it is suggested that ExAR in early puberty may serve as a predictive marker for the eventual development of PCO.

A Pertzelan, Institute of Pediatric and Adolescent Endocrinology, Children's Medical Center of Israel, Beilinson Medical Campus, Kaplan Street, Petah Tiqva 49202, Israel




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
R. L. Rosenfield
Identifying Children at Risk for Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 787 - 796.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
M. Guido, D. Romualdi, R. Suriano, M. Giuliani, B. Costantini, R. Apa, and A. Lanzone
Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome
Hum. Reprod., March 1, 2004; 19(3): 534 - 539.
[Abstract] [Full Text] [PDF]


Home page
CLIN PEDIATRHome page
M. S. Sothern and S. T. Gordon
Prevention of Obesity in Young Children: A Critical Challenge for Medical Professionals
Clinical Pediatrics, March 1, 2003; 42(2): 101 - 111.
[PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Azziz, V. Y. Black, E. S. Knochenhauer, G. A. Hines, and L. R. Boots
Ovulation After Glucocorticoid Suppression of Adrenal Androgens in the Polycystic Ovary Syndrome Is Not Predicted by the Basal Dehydroepiandrosterone Sulfate Level
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 946 - 950.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. P. Feuillan, J. V. Jones, K. Barnes, K. Oerter-Klein, and G. B. Cutler Jr.
Reproductive Axis after Discontinuation of Gonadotropin-Releasing Hormone Analog Treatment of Girls with Precocious Puberty: Long Term Follow-Up Comparing Girls with Hypothalamic Hamartoma to Those with Idiopathic Precocious Puberty
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 44 - 49.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Gennarelli, J. Holte, M. Stridsberg, U. Lundqvist, M. Massobrio, T. Bäckström, and C. Berne
Response of the Pituitary-Adrenal Axis to Hypoglycemic Stress in Women with the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 76 - 81.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 European Society of Endocrinology.